Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-09-02
2008-09-02
Huff, Sheela J (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S326000
Reexamination Certificate
active
10486989
ABSTRACT:
Immunogenic peptides of a melanoma antigen recognized by T cells, designated gp100, bioassays using the peptides to diagnose, assess or prognose a mammal afflicted with cancer, more specifically melanoma or metastatic melanoma, and use of the proteins and peptides as immunogens to inhibit, prevent or treat melanoma.
REFERENCES:
patent: 5262177 (1993-11-01), Brown et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5844075 (1998-12-01), Kawakami et al.
patent: 5874560 (1999-02-01), Kawakami et al.
patent: 5994523 (1999-11-01), Kawakami et al.
patent: 6537560 (2003-03-01), Kawakami et al.
patent: 0 563 485 (1993-10-01), None
patent: WO 93/20185 (1993-10-01), None
patent: 01/90197 (2001-11-01), None
patent: WO 02/080848 (2002-10-01), None
Kirkin et al, (1998, APMIS, 106 : 665-679).
George et al. (2005, Trends in Immunology 26(12):653-659).
Smith (1994, Clin Immunol, 41(4):841-849).
Ezzell (J. NIH Res, 1995, 7:46-49).
Spitler (Cancer Biotherapy, 1995, 10:1-3).
Roitt et al, 1998, Immunology, 4th ed, Mosby, London, (p. 7.7-7.8).
Holmes (Exp. Opin.Invest. Drugs, 2001, 10(3):511-519) (p. 7.7-7.8).
Lapointe et al. (2001, J. of Immunol. 167(8):4758-64).
Anichini et al., “Melanoma Cells and Normal Melanocytes Share Antigens Recognized by HLA-A2-Restricted Cytotoxic T Cell Clones from Melanoma Patients,”J. Exp. Med., 177, 989-998 (1993).
Barth et al., “Interferon γ and Tumor Necrosis Factor Have a Role in Tumor Regressions Mediated by Murine CD8+ Tumor-Infiltrating Lymphocytes,”J. Exp. Med., 173, 647-658 (1991).
Brichard et al., “The Tyrosinase Gene Codes for an Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas,”J. Exp. Med., 178, 489-495 (1993).
Cerundolo et al., “Presentation of Viral Antigen Controlled by a Gene in the Major Histocompatibility Complex,”Nature, 345, 449-452 (1990).
Chen et al., “Cancer-Testis Antigens: Targets for Cancer Immunotheraphy,”Cancer J. Sci. Am., 5, 16-17 (1999).
Chicz et al., “Specificity and Promiscuity among Naturally Processed Peptides Bound to HLA-DR Alleles,”J. Exp. Med., 178, 27-47 (1993).
Cormier et al., “Heterogeneous Expression of Melanoma-Associated Antigens and HLA-A2 in Metastatic Melanoma In Vivo,”Int. J. Cancer, 75, 517-524 (1998).
Coulie et al., “Precursor Frequency Analysis of Human Cytolytic T Lymphocytes Directed Against Autologous Melanoma Cells,”Int. J. Cancer, 50, 289-297 (1992).
Darrow et al., “The Role of HLA Class I Antigens in Recognition of Melanoma Cells by Tumor-Specific Cytotoxic T Lymphocytes: Evidence for Shared Tumor Antigens,”J. Immunol., 142(9), 3329-3335 (1989).
Dudley et al., “Antitumor Immunization with a Minimal Peptide Epitope (G9-209-2M) Leads to a Functionally Heterogeneous CTL Response,”J. Immunother., 22(4), 288-298 (1999).
GenBank Accession No. M32295.
Hom et al., “Common Expression of Melanoma Tumor-Associated Antigens Recognized by Human Tumor Infiltrating Lymphocytes: Analysis by Human Lymphocyte Antigen Restriction,”J. Immunother., 10, 153-164 (1991).
Hom et al., “Specific Release of Cytokines by Lymphocytes Infiltrating Human Melanomas in Response to Shared Melanoma Antigens,”J. Immunother., 13(1), 18-30 (1993).
Itoh et al., “Interleukin 2 Activation of Cytotoxic T-Lymphocytes Infiltrating into Human Metastatic Melanomas,”Cancer Res., 46, 3011-3017 (1986).
Kawakami, et al., “Identification of a Human Melanoma Antigen Recognized by Tumor-Infiltrating Lymphocytes Associated with in vivo Tumor Rejection,”Proc. Natl. Acad. Sci. USA,91, 6458-6462 (1994).
Kawakami et al., “Interleukin 4 Promotes the Growth of Tumor-Infiltrating Lymphocytes Cytotoxic for Human Autologous Melanoma,”J. Exp. Med.,168, 2183-2191 (1988).
Kawakami et al., “IL-4 Regulates IL-2 Induction of Lymphokine-Activated Killer Activity From Human Lymphocytes,”J. Immunol., 142(10), 3452-3461 (1989).
Kawakami et al., “Shared Human Melanoma Antigens: Recognition by Tumor-Infiltrating Lymphocytes in HLA-A2.1-Transfected Melanomas,”J. Immunol., 148(2), 638-643 (1992).
Kawakami et al., “T-Cell Recognition of Human Melanoma Antigens,”J. Immunother., 14, 88-93 (1993).
Kershaw et al., “Generation of Gene-Modified T Cells Reactive Against the Angiogenic Kinase Insert Domain-Containing Receptor (KDR) Found on Tumor Vasculature,”Hum. Gene Ther., 11, 2445-2452 (2000).
Lapointe et al., “Human Dendritic Cells Require Multiple Activation Signals for the Efficient Generation of Tumor Antigen-Specific T Lymphocytes,”Eur. J. Immunol., 30, 3291-3298 (2000).
Malcherek et al., “Supermotifs Enable Natural Invariant Chain-Derived Peptides to Interact with Many Major Histocompatibility Complex-Class II Molecules,”J. Exp. Med., 181, 527-536 (1995).
Mata et al., “Th1 T Cell Responses to HIV-1 Gag Protein Delivered by aListeria monocytogenesVaccine Are Similar to Those Induced by Endogenous Listerial Antigens,”J. Immunol., 163, 1449-1456 (1999).
Matloubian et al., “CD4+ T Cells Are Requied To Sustain CD8+Cytotoxic T-Cell Responses during Chronic Viral Infection,”J. Virol., 68(12), 8056-8063 (1994).
Muul et al., “Identification of Specific Cytolytic Immune Responses Against Autologous Tumor in Humans Bearing Malignant Melanoma,”J. Immunol., 138(3), 989-995 (1987).
Naviaux et al., “The pCL Vector System: Rapid Production of Helper-Free, High-Titer, Recombinant Retroviruses,”J. Virol., 70(8), 5701-5705 (1996).
O'Neil et al., “Detection of Shared MHC-Restricted Human Melanoma Antigens After Vaccinia Virus-Mediated Transduction of Genes Coding for HLA,”J. Immunol., 151(3), 1410-1418 (1993).
Ossendorp et al., “Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes Against Major Histocompatibility Complex Class II Negative Tumors,”J. Exp. Med., 187(5), 693-702 (1998).
Pardoll et al., “The Role of CD4+ T Cell Responses in Antitumor Immunity,”Curr. Opin. Immunol., 10, 588-594 (1998).
Parkhurst et al., “Improved Induction of Melanoma-Reactive CTL with Peptides From the Melanoma Antigen gp100 Modified at HLA-A*0201-Binding Residues,”J. Immunol., 157, 2539-2548 (1996).
Parry et al., “Autoreactivity Versus Autoaggression: A Different Perspective on Human Autoantigens,”Curr. Opin. Immunol., 10, 663-668 (1998).
Rammensee et al., “MHC Ligands and Peptide Motifs: First Listing,”Immunogenetics, 41, 178-228 (1995).
Reeves et al., “Retroviral Transduction of Human Dendritic Cells with a Tumor-Associated Antigen Gene,”Cancer Res., 56, 5672-5677 (1996).
Rosenberg et al., “Immunologic and Therapeutic Evaluation of a Synthetic Peptide Vaccine for the Treatment of Patients with Metastatic Melanoma,”Nat. Med., 4(3), 321-327 (1998).
Rosenberg, “Karnofsky Memorial Lecture. The Immunotherapy and Gene Therapy of Cancer,”J. Clin. Oncol., 10(2), 180-199 (1992).
Rosenberg et al., “Immunization of Cancer Patients Using Autologous Cancer Cells Modified by Insertion of the Gene for Tumor Necrosis Factor,”Hum. Gene Ther., 3, 57-73 (1992).
Rosenberg et al., “Immunization of Cancer Patients Using Autologous Cancer Cells Modified by Insertion of the Gene for Interleukin-2,”Hum. Gene Ther., 3, 75-90 (1992).
Rosenberg et al., “A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes,”Science, 233, 1318-1321 (1986).
Rosenberg et al., “Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma: A Preliminary Report,”N. Engl. J. Med., 319, 1676-1680 (1988).
Salgaller et al., “Immunization Against Epitopes in the Human Melanoma Antigen gp100 following Patient Immunization with Synthetic Peptides,”Cancer Res., 56, 4749-4757 (1996).
Hwu Patrick
LaPointe Rejean
Parkhurst Maria
Rosenberg Steven A.
Huff Sheela J
Leydig & Voit & Mayer
The United States of America as represented by the Secretary of
LandOfFree
Peptides of melanoma antigen and their use in diagnostic,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides of melanoma antigen and their use in diagnostic,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides of melanoma antigen and their use in diagnostic,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3929994